Showing results (31-40 of 831) with videos related to
Sort By:
Pageof 84
Blood|October 7, 2006
Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)Klaus Podar, Marc S Raab, Jing Zhang, et al.Expert Opinion on Emerging Drugs|March 3, 2009
Emerging therapies for multiple myelomaKlaus Podar, Yu-Tzu Tai, Teru Hideshima, et al.Blood|March 10, 2009
Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implicationsTeru Hideshima, Dharminder Chauhan, Tanyel Kiziltepe, et al.Proceedings of the National Academy of Sciences of the United States of America|June 7, 2005
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myelomaTeru Hideshima, James E Bradner, Jason Wong, et al.Blood|August 30, 2002
2-Methoxyestradiol overcomes drug resistance in multiple myeloma cellsDharminder Chauhan, Laurence Catley, Teru Hideshima, et al.Nature Reviews. Cancer|December 3, 2002
Molecular mechanisms of novel therapeutic approaches for multiple myelomaTeru Hideshima, Kenneth C AndersonInternational Journal of Hematology|September 2, 2011
Novel therapies in MM: from the aspect of preclinical studiesTeru Hideshima, Kenneth C AndersonInternational Journal of Hematology|March 12, 2013
Histone deacetylase inhibitors in the treatment for multiple myelomaTeru Hideshima, Kenneth C AndersonClinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivoTeru Hideshima, Paola Neri, Pierfranchesco Tassone, et al.Seminars in Hematology|June 26, 2012
Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studiesTeru Hideshima, Kenneth C AndersonPageof 84